Browse more cannabis research, findings, methods, and limitations.
A pilot RCT found 4 weeks of low-dose CBD (60mg/day) did not improve blood sugar control, gut microbiome composition, or inflammation in 16 overweight or obese adults.
An open-label study of 88 chronic pain patients found 58% achieved at least 50% pain reduction with full-spectrum cannabis, and 26% reduced or stopped other pain medications.
An Ontario population study found cannabis-related hospital visits were associated with 5.4x higher self-harm risk and 9.2x higher suicide risk over 3 years, even in those without pre-existing mental health conditions.
Combining a CB1 blocker with a NOP receptor activator worsened colitis in mice, revealing a cautionary interaction between the endocannabinoid and nociceptin systems.
CBD reversed elevated dopamine neuron activity in both male and female rats in a schizophrenia model and corrected memory deficits in males.
A survey of nearly 3,000 cannabis users in legal US states found two-thirds also used tobacco, with simultaneous use linked to higher cannabis problem severity.
Among 33,000+ matched people with alcohol use disorder, cannabis use disorder was associated with 40% lower risk of alcohol-related liver disease and 14% lower mortality.
Among people misusing prescription sleep aids, 55.5% also used marijuana, with two profiles: a common alcohol/marijuana/tobacco pattern and a riskier polysubstance pattern.
Mice lacking CB1 receptors in the hypothalamus had less joint damage and lower stress hormones with aging, suggesting the brain's cannabinoid system influences peripheral joint health.
In 91 healthy adults, blood endocannabinoid levels showed no broad association with pain sensitivity, though anandamide was linked to pressure pain thresholds.
A child died after eating hashish, with forensic analysis revealing chronic exposure to multiple drugs including THC, cocaine, heroin, and fentanyl.
Among 18-20 year old cannabis users in LA, use frequency stayed stable after legalization, though edible consumption increased.
A pilot in a residential recovery program found clients and staff reported medical cannabis reduced cravings and managed symptoms.
Protocol for a 200-teen RCT testing whether 8 weeks of cannabis abstinence reduces depression and suicidal ideation — using 8 daily phone surveys to capture the moment-by-moment relationship.
ACOEM guideline found no quality evidence supporting cannabis for common work-related pain conditions and recommended against use in safety-sensitive positions.
A review found CUD treatment success depends on duration, motivation, coping skills, self-efficacy, and therapeutic alliance, with sex, age, and comorbidity predicting who benefits.
First analysis of cyclic vomiting and cannabis hyperemesis syndrome in Mexican patients found CHS patients had higher tobacco and alcohol use than CVS patients.
A nano-formulated CBD preparation fully suppressed neuropathic pain in mice with a single dose by selectively quieting overactive pain circuits.
First-episode psychosis patients who showed cognitive deterioration had higher cannabis exposure and environmental risk scores than those who maintained cognitive function.
Combining an anti-inflammatory lipid mediator with cannabinoid receptor agonists produced enhanced pain relief in diabetic rats beyond either treatment alone.
Brazilian LGBTQ+ youth, especially those assigned female at birth, had nearly double the odds of cannabis use and started using substances earlier than heterosexual cisgender peers.
Chronic pain patients on medical cannabis reduced opioid use from 40mg to under 3mg daily over a year, but nearly half couldn't tolerate the cannabis treatment.
Biological drug testing in ER patients confirmed cannabis use increased nationally from 2008-2019, with the biggest increases in states that legalized recreational cannabis.
Cannabinoid receptor ligands reshaped energy metabolism in brain astrocytes, triggering calcium signaling, glycogen depletion, and increased metabolic output primarily through CB1 pathways.
Qualitative study found medical cannabis helped parents manage symptoms and be more patient, but stigma and legal fears created tension in their parenting identity.
Survey of 302 cannabis users found few perceived differences between vaping and smoking risks, though younger users and women saw more mental health benefits from vaping.
Males with a specific MAOA gene variant who experienced childhood sexual abuse were more likely to use cannabis for coping, but this combination was associated with lower aggression.
Nearly half of regular cannabis users exceeded zero-tolerance driving THC limits after 48+ hours of abstinence, raising questions about per se impairment laws.
Phase 2 trial found CBD reduced aromatase inhibitor joint pain in 44% of breast cancer patients, with an average 2.36-point improvement among completers.
Survey found nearly half of breast cancer patients used CBD, mainly for pain and insomnia, with mixed self-reported results.
Cannabis use among Washington State young adults continued rising through COVID while alcohol, cigarette, and e-cigarette use declined.
Blood levels of endocannabinoid-related molecules differed in substance use disorder patients, with distinct patterns when ADHD was also present.
FDA trial found 5.6% of healthy adults on consumer-level CBD doses developed significant liver enzyme elevations in 28 days.
Depression was associated with 30% higher odds of frequent cannabis use among Black college students.
Black college students who started marijuana before 14 were 3x more likely to report suicidal ideation.
Older chronic pain patients starting medical cannabis were 54% more likely to begin long-term opioids the following year.
Adolescents with incarcerated family members had significantly higher odds of early and current cannabis, alcohol, and nicotine use.
European survey of 35,789 cannabis users found 42% also used CBD for similar reasons.
Survey of 1,302 small-scale growers: 82% also grew other plants, with most starting as gardeners before adding cannabis.
Lifelong dietary fatty acid composition influenced adult rat behavior and modified adolescent THC effects on anxiety and impulsivity.
Canadian study: neighborhood deprivation and gentrification linked to higher cannabis use; immigrant neighborhoods showed lower use.
Pediatric palliative care cannabis clinic saw reduced hospitalizations and polypharmacy across 46 patients.
Ten-year study: all young children testing positive for cannabis had child protection activation, but caregivers rarely disclosed.
UK Biobank analysis of 25,000+ people found cannabis users had brain network patterns resembling younger brains and better cognitive performance.
BC cannabis compassion clubs created harm reduction through structural (access, safety, quality) and operational (compassion, low-threshold) dimensions.
Legal Canadian cannabis vape products contained metal particles from device components in both liquid and inhaled aerosol.
Among 82,180 pregnancies, partner substance problems were linked to 89% higher odds of prenatal cannabis use.
Projection: German legalization may produce 19x more health harm from increased use disorder than gains from reduced contamination.
Cancer survivors with four or more adverse childhood experiences had four times the odds of cannabis use, pointing to early trauma as a key factor in substance use patterns during survivorship.
Thiazide blood pressure medications have been unknowingly targeting the endocannabinoid system for over sixty years through the enzyme NAPE-PLD, generating protective anandamide signaling.